



JC01 Rec'd PCT/PTO 01 JUL 2005

CERTIFICATE OF MAILING

I hereby certify that the foregoing Information Disclosure Statement and the accompanying Concise Statement of Relevance of Non-English References, Additional Information, Form PTO-1449 (1 Sheets), 1 Search Report, and 4 references are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date indicated below:

Date: 6/29/05 By: Lina Mara

Attorney Docket No.: 101137-64

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT	:	Jacobus Thomas Wilhelumus Elisabeth Vogels
SERIAL NO.	:	10/534,519
CUSTOMER NO.	:	27387
FILED	:	May 11, 2005
FOR	:	Detection of Demyelination
ART UNIT	:	TBA
EXAMINER	:	TBA

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicants respectfully request that the Examiner consider the references listed on the attached Form PTO-1449.

I. Timeliness, Fees and Certifications in lieu of Fees

This information disclosure statement is being filed within three months of the filing date of the application, or within three months of entry into the national stage, or before the mailing of a first Office Action on the merits. Pursuant to 37 CFR § 1.97(b), consideration of this information disclosure statement does not require a fee or a statement under 37 CFR § 1.97(e). However, should the Assistant Commissioner determine that a fee is, in fact, due, the Assistant Commissioner is hereby authorized to charge the fee to Deposit Account No. 14-1263.

II. Copies of Listed References

Copies of all references listed on the attached Form PTO-1449 are being supplied.
Copies of U.S. patents are not included pursuant to Pre-OG Notice dated July 11, 2003.

III. Concise Statement of Relevance

All references listed on the attached Form PTO-1449 are in the English language, and, therefore, a concise statement of relevance is not required.

Consideration of the foregoing in relation to this application is respectfully requested.

Respectfully submitted,

NORRIS McLAUGHLIN & MARCUS, P.A.

By 

Bruce S. Londa
Reg. No. 33,531
875 Third Avenue
18th Floor
New York, New York 10022
(212) 808-0700

LIST OF PATENTS AND PUBLICATIONS APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Form PTO-1449)				Attorney Docket: 101137-64		Serial No.: 10/534,519	
				Applicant: Vogels		Examiner: TBA	
				Filing Date: May 11, 2005		Group: TBA	
U.S. PATENT DOCUMENTS							
Examiner's Initial		Document Number	Date	Name	Class	Sub Class	Filing Date If appropriate
	AA	6,181,134 B1	1/30/01	Wald	324	307	3/9/98
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub Class	Translation Yes No
	AB	WO 98/41882	9/24/98	PCT	G01R	33/483	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AC	F. Giubilei, et al.; "Blood Cholesterol and MRI Activity in First Clinical Episode Suggestive of Multiple Sclerosis"; ACTA Neurologica Scandinavica; 2002; Volume 106; pages 109-112.					
	AD	M. N. Degaonkar; "Sequential Proton MRS Study of Brain Metabolite Changes Monitored During a Complete Pathological Cycle of Demyelination and Remyelination in a Lysophosphatidyl Choline (LPC)-induced Experimental Demyelinating Lesion Model"; NMR Biomedicine; 2002; Volume 15; Pages 293-300.					
	AE	A.G. Droogan, et al.; "Comparison of Multiple Sclerosis Clinical Subgroups Using Navigated Spin Echo Diffusion-Weighted Imaging"; Magnetic Resonance Imaging; 1999; Volume 17, No. 5; Pages 653-661.					
EXAMINER:				DATE CONSIDERED:			
<ul style="list-style-type: none"> EXAMINER: Initial if Reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 							